secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aardvark Therapeutics, Inc. (AARD)
CIK:        0001774857
Form:       8-K
Filed at:   2026-10-08T20:14:11+00:00
Accession:  0001193125-26-417935
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Aardvark Therapeutics adds Abivax CSO David Zhang to board as ARD-101 regulatory decisions loom
--------------------------------------------------------------------------------

- David Zhang, Ph.D., MBA, appointed independent Class II director effective Oct. 7, 2026; he is Chief Strategy Officer of Abivax S.A. and a member of its Executive Committee.
- Zhang paid $40,000/year prorated cash plus a $500,000 option granted Oct. 7, 2026 that vests 1/36 monthly and accelerates in full on a change in control.
- At Abivax he led biometrics through positive topline readouts of two pivotal Phase 3 trials of obefazimod in ulcerative colitis.
- At MyoKardia he oversaw pivotal trial design, readout and the NDA for CAMZYOS (mavacamten) before the Bristol Myers Squibb acquisition; earlier 15 years at Genentech/Roche.
- Zhang said Aardvark is 'at a pivotal moment, with important decisions ahead for ARD-101' and cited navigating the regulatory landscape in Prader-Willi Syndrome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1774857/000119312526417935/0001193125-26-417935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1774857/000119312526417935/ck0001774857-20261006.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-417935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer